ArticleBMC ophthalmology2026
Vision-related quality of life after phacoemulsification combined with goniosynechialysis and goniotomy in patients with primary angle-closure glaucoma and cataract.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo assess vision-related quality of life by using patient-reported outcomes (PROs) measures after phacoemulsification with intraocular lens implantation (PEI) combined with goniosynechialysis (GSL) and goniotomy (GT) in patients with primary angle-closure glaucoma (PACG) and cataract, and explore its association with IOP, BCVA, and medication burden.
methodsThis retrospective study enrolled 31 eyes from 31 PACG patients who received PEI + GSL+GT from January 1, 2024 to February 1, 2025. Intraocular pressure (IOP), logMAR best corrected visual acuity (BCVA), number of topical intraocular pressure-lowering medications, and complications were detected at baseline and at postoperative 1-day, 1-week, 1-month, 3-month, 6-month and 12-month. The total score of Glaucoma Quality of Life 15 (GQL-15) and Glaucoma Symptom Scale (GSS) from baseline to 12 months was collected. Surgical success was estimated using Kaplan–Meier methods.
resultsIOP decreased from 27.2 ± 7.8 to 16.0 ± 3.2 mmHg at 12 months (95% CI, 8.4–13.9; P < 0.0001). The number of topical IOP-lowering drugs decreased from 2.55 ± 0.81 to 0.06 ± 0.25 (95% CI, 2.17–2.80; P < 0.0001). GQL-15 total score decreased from 36.3 ± 11.5 to 29.1 ± 10.0 (95% CI, 5.05–9.27; P < 0.0001). GSS total score increased from 71.2 ± 13.9 to 77.6 ± 12.8 (95% CI, 3.56–9.10; P < 0.0001). LogMAR BCVA improved from 1.14 ± 0.74 at baseline to 0.65 ± 0.74 at 12-month (95% CI, 0.28–0.71; P < 0.001). Twelve-month Kaplan-Meier success was 0.742 (95% CI, 0.550–0.862). Major complications were microhyphema (4/31, 12.9%), transient corneal edema (1/31, 3.2%), and suspected steroid-related postoperative IOP elevation (3/31, 9.7%). Microhyphema and corneal edema resolved within 1 week, and suspected steroid-related postoperative IOP elevation resolved after discontinuation of topical corticosteroids. No malignant glaucoma, persistent hypotony, or reoperation occurred. PRO changes showed no stable correlations with changes in IOP, BCVA, or medication burden.
conclusionsPEI + GSL+GT was associated with improved vision-related quality of life and lower IOP, reduced medication burden, and improved BCVA over 12 months. PROs provided complementary information that extends beyond the scope of conventional clinical metrics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.